Steve Colletti

Steve Colletti is the Chief Scientific Officer with a distinguished career spanning nearly three decades in the pharmaceutical industry. His expertise covers a wide array of therapeutic areas including cardiovascular and respiratory diseases, diabetes, obesity, immunological disorders, infectious diseases, neuroscience, and oncology. Colletti’s extensive background includes significant tenures at notable companies; he was previously the Senior Vice President of Drug Discovery R&D at Zymergen and the Chief Scientific Officer at Lodo Therapeutics. Prior to these roles, he amassed nearly 25 years of experience at Merck, where he led initiatives in small molecule, natural products, oligonucleotide, peptide, and fusion protein bioconjugate drug discovery. Notably, he built and directed the RNA Therapeutics Medicinal Chemistry department and was integral in the discovery of over a dozen preclinical candidates, advancing them to clinical development. His collaborative efforts extended to licensing and business development, evaluating external opportunities, and managing acquisitions. An accomplished inventor and scholar, Colletti has authored over 130 patents and publications. He earned his Ph.D. in chemistry from Boston University and completed a postdoctoral fellowship in chemistry at the Scripps Research Institute under the auspices of the National Institutes of Health.